Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 18:2022:2802892.
doi: 10.1155/2022/2802892. eCollection 2022.

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment

Qianying Yu  1 , Xiaopei Ge  1 , Mingyi Jing  1 , Xiongfei Mi  1 , Jing Guo  1 , Min Xiao  1 , Qing Lei  1 , Mingling Chen  1
Affiliations
Meta-Analysis

A Systematic Review with Meta-Analysis of Comparative Efficacy and Safety of Risankizumab and Ustekinumab for Psoriasis Treatment

Qianying Yu et al. J Immunol Res. .

Abstract

Biological targeted therapy serves as a new alternative treatment for psoriasis due to its minimal side effects. This study is aimed at examining the drug effectiveness and safety of risankizumab and ustekinumab for psoriasis treatment, so as to provide a reference for clinical decision-making. Databases from Embase, Web of Science, PubMed, and Cochrane Library were gathered, starting from inception to March 1, 2022, for randomized controlled trials regarding risankizumab and ustekinumab for psoriasis treatment. All retrieved articles were carefully selected in strict accordance with a set of inclusion and exclusion criteria. Stata 15.0 and RevMan 5.4 were applied to perform meta-analysis and risk of bias assessment. A total of two trials with three NCTs were selected, with 384 participants in the risankizumab group and 140 participants in ustekinumab. Meta-analysis showed that in the long-term and short-term PASI100, risankizumab was more effective than ustekinumab (RR = 2.27, 95% CI (1.77, 2.90), p < 0.05; RR = 2.33, 95% CI (1.75, 3.08), p < 0.05). In PASI90, RR = 1.77, 95% CI (1.54, 2.03), and p < 0.05 and RR = 1.72, 95% CI (1.48, 2.00), and p < 0.05. In short-term PASI75, RR = 1.23, 95% CI (1.13, 1.34), and p < 0.05. In sPGA of 0, the results at week-16 and week-52 showed that risankizumab was significantly more effective than ustekinumab (RR = 2.24, 95% CI (1.67, 3.01), p < 0.05; RR = 2.30, 95% CI (1.80, 2.95), p < 0.05). Risankizumab was significantly more effective than ustekinumab in improving the quality of life and PSS scores (RR = 1.48, 95% CI (1.26, 1.75), p < 0.05; RR = 2.01, 95% CI (1.41, 2.85), p < 0.05). Nevertheless, risankizumab and ustekinumab did not show significant difference in the incidence of adverse responses (RR = 1.02, 95% CI (0.75, 1.39), p > 0.05). Risankizumab was more effective than ustekinumab for the treatment of psoriasis. The adverse reactions of both risankizumab and ustekinumab were similar and could be tolerated. Risankizumab might be a better alternative option for their treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow diagram of literature search.
Figure 2
Figure 2
(a, b) Risk of bias of included studies.
Figure 3
Figure 3
Forest plot of long-term PASI scores.
Figure 4
Figure 4
Forest plot of short-term PASI scores.
Figure 5
Figure 5
Forest plot of long-term sPGA scores.
Figure 6
Figure 6
Forest plot of short-term sPGA scores.
Figure 7
Figure 7
Forest plot of sPGA scores of 0/1.
Figure 8
Figure 8
Forest plot of sPGA scores of 0.
Figure 9
Figure 9
Forest plot of PSS.
Figure 10
Figure 10
Forest plot of quality of life.
Figure 11
Figure 11
Forest plot of adverse reactions.
See this image and copyright information in PMC

References

    1. Griffiths C. E. M., Armstrong A. W., Gudjonsson J. E., Barker J. N. W. N. Psoriasis. Lancet . 2021;397(10281):1301–1315. doi: 10.1016/S0140-6736(20)32549-6. - DOI - PubMed
    1. Langley R. G., Krueger G. G., Griffiths C. E. Psoriasis: epidemiology, clinical features, and quality of life. Annals of the Rheumatic Diseases . 2005;64(suppl_2):ii18–ii23. doi: 10.1136/ard.2004.033217. - DOI - PMC - PubMed
    1. Griffiths C. E., Barker J. N. Pathogenesis and clinical features of psoriasis. Lancet . 2007;370(9583):263–271. doi: 10.1016/S0140-6736(07)61128-3. - DOI - PubMed
    1. González-Parra S., Daudén E. Psoriasis and depression: the role of inflammation. Actas Dermosifiliogr (Engl Ed) . 2019;110(1):12–19. doi: 10.1016/j.ad.2018.05.009. - DOI - PubMed
    1. Hölsken S., Krefting F., Schedlowski M., Sondermann W. Common fundamentals of psoriasis and depression. Acta Dermato-Venereologica . 2021;101(11):p. adv00609. doi: 10.2340/actadv.v101.565. - DOI - PMC - PubMed